Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations, Upcoming Webinar Hosted by Xtalks
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: PR Web
TORONTO (PRWEB) January 13, 2020 In 2018, the US Food and Drug Administration (FDA) released updated guidelines on drug development. That same year, the European Medicines Agency (EMA) also took the initiative to implement additional regulations supporting drug development in Europe. Since the release of these guidelines, overlooking factors such as acceptability, excipient considerations and caregiver instructions are no longer an option. On Wednesday, January 29, 2020 at 11am EST (4pm GMT/UK), join Matt Ling, Ph. D., Director of Scientific Services, at Catalent and Rachel Meyers, Pharm D., BCPS, BCPPS, FPPA, Clinical Associate Professor at Ernest Mario School of Pharmacy, Rutgers University and Pediatric Clinical Pharmacist, Saint Barnabas Medical Center for a live webinar where they will discuss: The impact of age-appropriate dose forms for pediatrics Insights into caregiver perspectives A case study on real-world medications and acceptability assessment Solutions that addre
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Ozempic, Novo's $1,000 Diabetes Drug, Can Be Made for Less Than $5 a Month, Study Says [BNN Bloomberg (Canada)]BNN Bloomberg
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]Yahoo! Finance
- Global Contract Development and Manufacturing Organization (CDMO) Analysis Report 2024: Market to Reach $256.9 Billion in 2029, Driven by Growing Biologics, Orphan Drugs, and Emerging Markets [Yahoo! Finance]Yahoo! Finance
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 3/19/24 - Form 4
- 3/15/24 - Form 144
- 3/12/24 - Form 144
- CTLT's page on the SEC website